AR110904A1 - ANTI-TGF-b ANTIBODIES AND ITS USE - Google Patents

ANTI-TGF-b ANTIBODIES AND ITS USE

Info

Publication number
AR110904A1
AR110904A1 ARP180100118A ARP180100118A AR110904A1 AR 110904 A1 AR110904 A1 AR 110904A1 AR P180100118 A ARP180100118 A AR P180100118A AR P180100118 A ARP180100118 A AR P180100118A AR 110904 A1 AR110904 A1 AR 110904A1
Authority
AR
Argentina
Prior art keywords
tgf
antibody
seq
conditions
antibodies
Prior art date
Application number
ARP180100118A
Other languages
Spanish (es)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR110904A1 publication Critical patent/AR110904A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La solicitud proporciona un anticuerpo pan-TGF-b mejorado para el tratamiento de afecciones que están mediadas por TGF-b, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1. Reivindicación 1: Un anticuerpo monoclonal aislado que se une específicamente a TGF-b1, TGF-b2, y TGF-b3 humano, que comprende las regiones determinantes de la complementariedad de cadena pesada (CDR) 1 - 3 de SEQ ID Nº 1 y las CDR1 - 3 de cadena ligera de SEQ ID Nº 2, en donde el anticuerpo comprende una región constante de IgG4 que tiene una prolina en la posición 228 (numeración UE).The application provides an improved pan-TGF-b antibody for the treatment of conditions that are mediated by TGF-b, including autoimmune diseases, fibrotic conditions, and cancers. Uses and uses of the antibody are also provided together with other immunomodulatory agents such as an anti-PD-1 antibody. Claim 1: An isolated monoclonal antibody that specifically binds TGF-b1, TGF-b2, and human TGF-b3, comprising the heavy chain complementarity determining (CDR) regions 1-3 of SEQ ID No. 1 and Light chain CDR1-3 of SEQ ID No. 2, wherein the antibody comprises a constant region of IgG4 having a proline at position 228 (EU numbering).

ARP180100118A 2017-01-20 2018-01-18 ANTI-TGF-b ANTIBODIES AND ITS USE AR110904A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
AR110904A1 true AR110904A1 (en) 2019-05-15

Family

ID=66669189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100118A AR110904A1 (en) 2017-01-20 2018-01-18 ANTI-TGF-b ANTIBODIES AND ITS USE

Country Status (2)

Country Link
KR (2) KR102568885B1 (en)
AR (1) AR110904A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3312195B1 (en) * 2013-03-20 2019-10-09 Genzyme Corporation Methods for treating osteogenesis imperfecta
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
ES2820768T3 (en) * 2015-04-03 2021-04-22 Xoma Technology Ltd Cancer treatment using TGF-beta and PD-1 inhibitors

Also Published As

Publication number Publication date
KR20190105077A (en) 2019-09-11
KR102568885B1 (en) 2023-08-21
KR20230124768A (en) 2023-08-25

Similar Documents

Publication Publication Date Title
PE20200734A1 (en) ANTI-TGF-BETA ANTIBODIES AND THEIR USE
CL2022000328A1 (en) Humanized antibody that specifically binds to the human transferrin receptor (tfr); pharmaceutical composition; use of the humanized antibody to prepare a medicament useful for treating a neurological disorder. (divisional application no. 3207-2017)
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
AR104213A1 (en) ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS
PE20190398A1 (en) NEW ANTIBODIES THAT SPECIFICALLY BIND AND USES OF THE ZIKA VIRUS EPITHOPES
ECSP17005649A (en) HUMANIZED ANTI-TAU ANTIBODIES
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
UY36692A (en) ANTI-CD40 ANTIBODIES AND USES OF THE SAME
PE20200384A1 (en) METHOD OF MANUFACTURE OF BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201991729A1 (en) ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
PE20211887A1 (en) ANTIGENIC CHIMERICAL RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF BINDING TO ANTIGENS, WHICH SELECTIVELY JOINES THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS
AR101875A1 (en) ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME
PE20161389A1 (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA202090800A1 (en) NEW ANTI-CD3-EPSILON ANTIBODIES
AR096601A1 (en) ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
CL2020002600A1 (en) Anti-programmed death antibody-ligand 1 and its use
MX2020008122A (en) Anti-pd-1 antibodies.
EA201992460A1 (en) BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION
AR119507A1 (en) TRISPECIFIC ANTI-PD-1/LAG3/TIGIT ANTIBODIES AND BISPECIFIC ANTI-PD-1/LAG3 ANTIBODIES
AR109683A1 (en) ANTIBODIES AGAINST FACTOR XI AND ITS USES